Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation

References

• Passweg J, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51:786–792.
   PubMed Web of Science ®Google Scholar
• Pidala J, Kurland BF, Chai X, et al. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. Haematologica. 2011;96:1528–1535.
   PubMed Web of Science ®Google Scholar
• Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333–1338.
   PubMed Web of Science ®Google Scholar
• Hobbs GS, Perales MA. Effects of T-cell depletion on allogeneic hematopoietic stem cell transplantation outcomes in AML patients. J Clin Med. 2015;4:488–503.
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562.
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, LeRademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117:6963–6970.
   PubMed Web of Science ®Google Scholar
• Storek J, Mohty M, Boelens JJ. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21:959–970.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Nishihori T, Otrock ZK, et al. Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1288–1300.
   PubMed Web of Science ®Google Scholar
• Jakubowski AA, Small TN, Young JW, et al. T cell-depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007;110:4552–4559.
   PubMed Web of Science ®Google Scholar
• Handgretinger R. Negative depletion of CD3(+) and TcRαβ(+) T cells. Curr Opin Hematol. 2012;19:434–439.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Roosnek E, Mermillod B, et al. Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biol Blood Marrow Transplant. 2006;12:102–110.
   PubMed Web of Science ®Google Scholar
• Beauverd Y, Roosnek E, Tirefort Y, et al. Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion. Biol Blood Marrow Transplant. 2014;20:1322–1328.
   PubMed Web of Science ®Google Scholar
• Beauverd Y, Roosnek E, Tirefort Y, et al. Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. Bone Marrow Transplant. 2016;51:955–960.
   PubMed Web of Science ®Google Scholar
• Armand P, Gibson CJ, Cutler C, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120:905–913.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kato S, Oiwa-Monna M, et al. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies. Leuk Lymphoma. 2016;57(9):2126–2132.
   PubMed Web of Science ®Google Scholar
• Solh M, Zhang X, Connor K, et al. Factors predicting graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation: multivariable analysis from a single center. Biol Blood Marrow Transplant. 2016;22:1403–1409.
   PubMedGoogle Scholar
• Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–3671.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Peffault de Latour R, DeFor TE, et al. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. Haematologica. 2016;101:764–772.
   PubMed Web of Science ®Google Scholar
• Ravinet A, Cabrespine A, Socie G, et al. Impact of thymoglobulin by stem cell source (peripheral blood stem cell or bone marrow) after myeloablative stem cell transplantation from HLA 10/10-matched unrelated donors. A Report From the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Transplantation. 2016;100:1732–1739.
   PubMed Web of Science ®Google Scholar
• Kuriyama K, Fuji S, Inamoto Y, et al. Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. Int J Hematol. 2016;103:453–460.
   PubMed Web of Science ®Google Scholar
• Kroger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43–53.
   PubMed Web of Science ®Google Scholar
• Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17:164–173.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Esterni B, Castagna L, et al. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer. 2013;119:986–992.
   PubMed Web of Science ®Google Scholar
• Baron F, Labopin M, Blaise D, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49:389–396.
   PubMed Web of Science ®Google Scholar
• Binkert L, Medinger M, Halter JP, et al. Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015;50:1331–1336.
   PubMed Web of Science ®Google Scholar
• Willemsen L, Jol-van der Zijde CM, Admiraal R, et al. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. Biol Blood Marrow Transplant. 2015;21:473–482.
   PubMedGoogle Scholar
• Na IK, Wittenbecher F, Dziubianau M, et al. Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients. Haematologica. 2013;98:23–30.
   PubMed Web of Science ®Google Scholar
• Servais S, Menten-Dedoyart C, Beguin Y, et al. Impact of pre-transplant anti-T cell globulin (ATG) on immune recovery after myeloablative allogeneic peripheral blood stem cell transplantation. PLoS One. 2015;10:e0130026.
   PubMed Web of Science ®Google Scholar
• Chapuis AG, Ragnarsson GB, Nguyen HN, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med. 2013;5:174ra27.
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Labopin M, Ciceri F, et al. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51:610–611.
   PubMed Web of Science ®Google Scholar